Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 9 METERS BIOPHARMA, INC.INNT · Entity 114271 | COO and Chief Medical Officer | August 24, 2018 | August 28, 2018 |
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | September 02, 2026 | September 04, 2026 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | June 17, 2025 | June 18, 2025 |
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | December 15, 2021 | December 17, 2021 |
| NeuBase Therapeutics, Inc.OHRP · Entity 109568 | Director | October 16, 2017 | October 18, 2017 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | January 09, 2026 | January 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
9 METERS BIOPHARMA, INC.
Report date August 24, 2018 · Filed August 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 100 |
Reported balance
After 2018-08-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-08-24 · Purchase · Acquired 100 · Balance 100 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 500 |
Reported balance
After 2018-08-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-08-24 · Purchase · Acquired 400 · Balance 500 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 547 |
Reported balance
After 2018-08-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-08-27 · Purchase · Acquired 47 · Balance 547 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 800 |
Reported balance
After 2018-08-27 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-08-27 · Purchase · Acquired 253 · Balance 800 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 900 |
Reported balance
After 2018-08-27 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2018-08-27 · Purchase · Acquired 100 · Balance 900 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
| Common stockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 1,400 |
Reported balance
After 2018-08-24 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-08-24 · Purchase · Acquired 500 · Balance 1,400 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
Actinium Pharmaceuticals, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,000 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Grant · Acquired 18,000 · Balance 18,000 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-09-02 | Direct | 27,000 |
Reported balance
After 2026-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-02 · Grant · Acquired 27,000 · Balance 27,000 F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
Avalo Therapeutics, Inc.
Report date June 17, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2035-06-17 | Direct | 20,100 |
Reported balance
After 2025-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-17 · Grant · Acquired 20,100 · Balance 20,100 F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date.
BRAINSTORM CELL THERAPEUTICS INC.
Report date December 15, 2021 · Filed December 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2021-12-15 transaction · row 1
1 source rowRow 1 · 2021-12-15 · Grant · Acquired 2,000 · Balance 6,000 F1: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021. |
| Common StockSEC Table I · non-derivative | IndirectBy Meadowlark Management LLC | 7,175 |
Reported balance
Holding disclosure · report date 2021-12-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,175 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.
F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.
NeuBase Therapeutics, Inc.
Report date October 16, 2017 · Filed October 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2022-10-15 | Direct | 170,000 |
Reported balance
After 2017-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-16 · Grant · Acquired 170,000 · Balance 170,000 F1: 1/3 of the shares of common stock subject to the stock option became exercisable immediately, and 1/3 of the shares of common stock subject to the stock option will become exercisable on each of October 16, 2018 and October 16, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the shares of common stock subject to the stock option became exercisable immediately, and 1/3 of the shares of common stock subject to the stock option will become exercisable on each of October 16, 2018 and October 16, 2019.
TENAX THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 30,000 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 30,000 · Balance 30,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,200.00 · Expires 2031-06-10 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 100,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 80,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Meadowlark Management, LLC | 1,993 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,993 F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097742 · ownership.xml · derivative · entry 2 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2036-09-02 F2 · derivative.exercise_date: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097742 · ownership.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,000 F1 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 01:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001492647-26-000001 · primary_doc.xml · derivative · entry 2 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-01-09 Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 23:43 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 1,900 | $7.52 | $14,279.83 |
DisclosureSEC source: 0001492647-25-000003 · primary_doc.xml · nonDerivative · entry 2 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,993 F1 · price: This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 23:16 UTC Amendment | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 1,900 | $7.52 | $14,279.83 |
DisclosureSEC source: 0001492647-25-000004 · primary_doc.xml · nonDerivative · entry 2 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Meadowlark Management, LLC Disclosed balance after: 1,993 F2 · price: This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:43 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 93 | $7.15 | $664.95 |
DisclosureSEC source: 0001492647-25-000003 · primary_doc.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93 Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 23:16 UTC Amendment | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 93 | $7.15 | $664.95 |
DisclosureSEC source: 0001492647-25-000004 · primary_doc.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Meadowlark Management, LLC Disclosed balance after: 93 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 12:14 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001654954-25-007739 · section16.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-07-01 Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 16:13 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 20,100 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001578563-25-000319 · primary_doc.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2035-06-17 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:22 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001213900-25-028230 · ownership.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2034-11-01 F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:22 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 3,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000199 · primary_doc.xml · derivative · entry 3 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,333 Underlying: Common Stock · 3,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F3 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:22 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 3,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-25-000199 · primary_doc.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 00:49 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001654954-24-015471 · section16.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-10 Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 17:21 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 500 | $13.00 | $6,500.00 |
DisclosureSEC source: 0001578563-24-000441 · primary_doc.xml · nonDerivative · entry 2 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Meadowlark Management, LLC Disclosed balance after: 1,000 F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 17:21 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 500 | $12.50 | $6,249.50 |
DisclosureSEC source: 0001578563-24-000441 · primary_doc.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Meadowlark Management, LLC Disclosed balance after: 500 F1 · price: This transaction was executed in multiple trades ranging from $12.00 to $12.50. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 17:12 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001213900-24-094632 · ownership.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-11-01 F1 · derivative.exercise_price: Represents a grant of stock options granted in connection with the Reporting Person's appointment as a director of the Issuer's Board of Directors. The exercise price represents the closing stock price of the Issuer's common stock, par value $0.001 per share, on November 1, 2024, the date of the grant. F2 · derivative.exercise_date: The options shall vest as follows: (i) 28% of the options shall vest on the 12-month anniversary of the date of grant, and (ii) 2% of the options shall vest each month from the date of grant, until fully vested. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 16:47 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantRestricted Stock Units · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000368 · primary_doc.xml · derivative · entry 2 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date. F3 · derivative.exercise_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F3 · derivative.expiration_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 16:47 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 24,600 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001578563-24-000368 · primary_doc.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,600 Underlying: Common Stock · 24,600 shares Expires 2034-08-13 F1 · derivative.exercise_date: The stock option vests 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:04 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,334 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001628280-23-042492 · wk-form4_1703192659.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2033-12-20 F1 · shares: The stock option will vest in full on December 20, 2024, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 16:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,575 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001628280-23-024230 · wk-form4_1688587518.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,575 Underlying: Common Stock · 4,575 shares Expires 2033-06-30 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 16:09 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,167 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001628280-23-010589 · wf-form4_168063897592978.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 1,167 shares Expires 2033-03-31 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 16:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 410 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001628280-23-000082 · wf-form4_167278029177365.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410 Underlying: Common Stock · 410 shares Expires 2032-12-30 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 16:28 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 605 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001628280-22-025858 · wf-form4_166482890030466.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605 Underlying: Common Stock · 605 shares Expires 2032-09-30 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 16:00 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,338 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001578563-22-000024 · primary_doc.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,338 Underlying: Common Stock · 4,338 shares Expires 2032-06-30 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001578563-22-000020 · primary_doc.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-14 F1 · shares: The stock option will vest in full on June 14, 2023, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 11, 2022 00:36 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001654954-22-008233 · section16.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-09 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:13 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 2,985 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001578563-22-000009 · primary_doc.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,985 Underlying: Common Stock · 2,985 shares Expires 2032-03-31 F1 · shares: 100% of the stock option will immediately vest on the date that it is granted. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:28 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 737 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001062993-22-000250 · form4.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737 Underlying: Common Stock · 737 shares Expires 2031-12-31 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151214 · tm2135659-3_4seq1.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148745 · tm2135032-1_4.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 16:18 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001878894-21-000022 · edgar.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-11-10 F1 · derivative.exercise_date: The stock option will vest in three substantially equal installments on November 10, 2022, November 10, 2023 and November 10, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001654954-21-006930 · section16.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2031-06-10 Read SEC document |
| December 12, 2019 Filed Feb 14, 2020 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021982 · tm205737d2_4.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 14:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 1,475 | $3.39 | $5,000.25 |
DisclosureSEC source: 0001144204-19-000986 · tv509629_4.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 7,175 F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 16:33 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 100 | $4.94 | $494.00 |
DisclosureSEC source: 0001551986-18-000017 · wf-form4_153548837301387.xml · nonDerivative · entry 5 Almenoff June Sherie · CIK 0001492647 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 900 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 16:33 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 253 | $4.96 | $1,254.88 |
DisclosureSEC source: 0001551986-18-000017 · wf-form4_153548837301387.xml · nonDerivative · entry 4 Almenoff June Sherie · CIK 0001492647 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 800 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 16:33 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 47 | $4.90 | $230.30 |
DisclosureSEC source: 0001551986-18-000017 · wf-form4_153548837301387.xml · nonDerivative · entry 3 Almenoff June Sherie · CIK 0001492647 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 547 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 16:33 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 500 | $4.85 | $2,425.00 |
DisclosureSEC source: 0001551986-18-000017 · wf-form4_153548837301387.xml · nonDerivative · entry 6 Almenoff June Sherie · CIK 0001492647 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 1,400 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 16:33 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 400 | $4.99 | $1,996.00 |
DisclosureSEC source: 0001551986-18-000017 · wf-form4_153548837301387.xml · nonDerivative · entry 2 Almenoff June Sherie · CIK 0001492647 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 500 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 16:33 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 100 | $4.85 | $485.00 |
DisclosureSEC source: 0001551986-18-000017 · wf-form4_153548837301387.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 100 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 10:06 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 5,700 | $3.50 | $19,950.00 |
DisclosureSEC source: 0001144204-18-015059 · tv488679_4.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 5,700 F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 14:50 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 5,700 | $3.50 | $19,950.00 |
DisclosureSEC source: 0001144204-18-015760 · tv488977_4a.xml · nonDerivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Meadowlark Management LLC Disclosed balance after: 5,700 F2 · kind: This Form 4/A is being filed to reflect that this was an open market purchase of the Issuer's securities (On March 16, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d). F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:01 UTC | NeuBase Therapeutics, Inc. OHRP · Entity 109568 | GrantStock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001387131-17-005087 · almenoff-form4_101617.xml · derivative · entry 1 Almenoff June Sherie · CIK 0001492647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2022-10-15 F1 · derivative.exercise_date: 1/3 of the shares of common stock subject to the stock option became exercisable immediately, and 1/3 of the shares of common stock subject to the stock option will become exercisable on each of October 16, 2018 and October 16, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.